523 related articles for article (PubMed ID: 27783593)
1. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
3. CCL3 is a key mediator for the leukemogenic effect of
Dong L; Zheng H; Qu CK
Blood; 2017 Sep; 130(12):1471-1474. PubMed ID: 28751523
[No Abstract] [Full Text] [Related]
4. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
[TBL] [Abstract][Full Text] [Related]
5. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
6. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
[TBL] [Abstract][Full Text] [Related]
7. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
8. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
[TBL] [Abstract][Full Text] [Related]
9. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
[TBL] [Abstract][Full Text] [Related]
10. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
11. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
12. JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β.
Yan Y; Dong L; Chen C; Bunting KD; Li Q; Stieglitz E; Loh ML; Qu CK
Blood Adv; 2022 Jan; 6(1):200-206. PubMed ID: 34555844
[TBL] [Abstract][Full Text] [Related]
13. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
14. [Multiple granular cell tumours in a patient with Noonan's syndrome and juvenile myelomonocytic leukaemia].
Castagna J; Clerc J; Dupond AS; Laresche C
Ann Dermatol Venereol; 2017 Nov; 144(11):705-711. PubMed ID: 28728859
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
16. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
17. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Yang W; Wang J; Moore DC; Liang H; Dooner M; Wu Q; Terek R; Chen Q; Ehrlich MG; Quesenberry PJ; Neel BG
Nature; 2013 Jul; 499(7459):491-5. PubMed ID: 23863940
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
[TBL] [Abstract][Full Text] [Related]
20. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Arranz L; Sánchez-Aguilera A; Martín-Pérez D; Isern J; Langa X; Tzankov A; Lundberg P; Muntión S; Tzeng YS; Lai DM; Schwaller J; Skoda RC; Méndez-Ferrer S
Nature; 2014 Aug; 512(7512):78-81. PubMed ID: 25043017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
